Quarterly report pursuant to Section 13 or 15(d)

Business (Details)

v3.21.1
Business (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Jun. 11, 2020
USD ($)
shares
Jan. 31, 2021
USD ($)
shares
Mar. 31, 2021
USD ($)
product
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Subsequent Event [Line Items]          
Sale of stock (in shares) | shares   13,971,889      
Cash and cash equivalents     $ 38,292 $ 5,659 $ 18,919
Net loss     (30,680) (21,117)  
Net cash used in operating activities     (18,316) $ (5,739)  
(Accumulated deficit) retained earnings     $ (208,470)   $ (177,790)
Warrant          
Subsequent Event [Line Items]          
Sale of stock (in shares) | shares   1,676,923      
Underwritten Public Offering          
Subsequent Event [Line Items]          
Sale of stock (in shares) | shares 15,180,000 13,971,889      
Net proceeds $ 35,400 $ 37,700      
Neurological Clinical And Preclinical Stage Compounds          
Subsequent Event [Line Items]          
Number of products in development | product     2    
Clinical Stage          
Subsequent Event [Line Items]          
Number of products in development | product     4